INTRODUCTION
This update summarizes articles and guidelines published in the last year that may impact general internists' women's health clinical practice (Table 1) .
METHODS
We reviewed the contents of leading medical journals including: the New England Journal of Medicine, the Journal of the American Medical Association, Annals of Internal Medicine, Archives of Internal Medicine, British Medical Journal, Lancet, Obstetrics and Gynecology, American Journal of Obstetrics and Gynecology, Journal of General Internal Medicine, PLOS Medicine, American Journal of Public Health, Circulation, Diabetes, and Diabetes Care between March 1, 2010 and February 28, 2011 . We also reviewed updates to the Cochrane database of systematic reviews, Guideline Clearinghouse, and the articles highlighted by the ACP Journal Club, Journal Watch, and Journal Watch Women's Health. Finally, we performed a MEDLINE search using the medical subject heading, "sex factors." Those abstracts rated in the top third of importance by any author were read closely and rated by all authors. A process of individual ratings and multiple discussions was then used to reach consensus about the most important articles published in the last year.
ISSUES FOR REPRODUCTIVE AGED WOMEN
Abdool Karim Q, Abdool Karim S, Frohlich J. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science. 2010;329 (5996):1168-74.
What Was Known? Women are disproportionately affected by the HIV epidemic, yet have few ways to protect themselves from sexually transmitted infections. Over the last 20 years, six microbicides have been studied; none provide meaningful protection against HIV infection.
What this Study Adds
This double-blind, randomized, placebocontrolled trial followed 889 HIV-negative, South African women who applied a 1% tenofovir vaginal gel 12 h before and 12 h after intercourse. Over 30 months of follow-up, the gel was found to have an acceptable safety profile and reduced HIV incidence by 39%.
How Should I Change my Practice? The US FDA has previously approved oral tenofovir and recently "fast tracked" the 1% gel, creating hope it may be available to our patients in 2012. What Was Known? Tranexamic acid inhibits the activation of plasminogen, increasing clot formation. Injectable tranexamic acid was FDA approved in 1986; an oral formulation has been safely used in Europe for the last 40 years and was FDA approved in 2009. 1 What this Study Adds. In this RCT (n=196), women treated with 3.9 g/day of tranexamic acid for 5 days with each menses had significant and personally meaningful reductions in menstrual blood loss at 1 month that were consistent to 6 months. In addition, women reported decreased social and physical limitations with menses.
How Should I Change my Practice? Oral transexamic acid is a new therapeutic alternative for providing short-term relief for menorrhagia, though a prior study found a levongestrel IUD was more effective than transexamic acid in providing longterm relief. What Was Known? Oral contraceptive pills (OCPs) are the most commonly used form of reversible contraception in the US, 3 and receiving a year's worth of pills upon initiating OCP use does not reduce preventive services such as Pap or chalmydia testing. What Was Known? First trimester induced abortion is one of the most commonly US performed surgical procedures. 5 What this study adds: In this study from multiple Danish registries, the investigators found that first trimester abortion did not affect rates of psychiatric contact (p=0.19) in the 9 months before or 12 months after the procedure (n=84,620). However, rates of psychiatric contact were increased after childbirth (p<0.001) for 6 to 9 months; rates of psychiatric contact for affective disorder were highest in the first month postpartum (RR= 3.79, 95% CI 2.86-5.02), but remained elevated 7-9 months postpartum (RR = 1.69, 1.31-2.17). Similarly, rates of psychiatric contact for neurotic, stressrelated, or somatoform disorders were highest 1 month postpartum and remained elevated for 7-9 months postpartum (RR=1.33 (1.11-1.60).
How should I change my practice? Women can be reassured that first trimester abortion does not increase the risk of mental disorder. Routine screening for postpartum mental disorder may be useful. What Was Known? Eating disorders, such as anorexia (Ana) and bulimia (Mia), are highly prevalent. Adolescents who frequent pro-eating disorder websites are less satisfied with their bodies and practice disordered eating longer than peers not using these sites. 6 Little is systematically known about the content of these sites.
DISEASES OF EARLY ADULTHOOD INTO MID-LIFE
What this Study Adds. This is the first large systematic review of pro-eating disorder websites. Investigators used Yahoo and Google search engines to find 180 active websites, forums, journals, or blogs focusing on pro-eating disorder information. Two reviewers independently coded the content using 64 variables organized into six themes (site logistics, site accessories, "thinspiration" materials, recovery, perceived themes, and perceived harm). Ninety-one percent of the websites were publicly accessible and 79% were interactive, wherein users could post content or use tools (e.g., diet calculators). Pro-anorexia content was provided on 84% of websites, pro-bulimia on 64%, thinspiration images or prose to inspire weight loss on 85%, and overt suggestions for engaging in eating-disordered behavior on 83%. Only 38% of websites offered recovery advice or a link to such information. The What this Study Adds. This 5-year prospective cohort study enrolled 1,995 women from four outpatient radiology facilities. Surveys were administered at baseline and at years 2, 4, and 5. Mammograms were reviewed by a blinded radiologist to determine the presence of BAC. At baseline, the mean age was 56.3 years, 95% were white, 61% post-menopausal, and 16.3% were BAC-positive. The BAC-positive group was older than the BAC-negative group (69 vs 54 years, p<0.001)) and had a higher prevalence of most CHD risk factors (hypertension, hypercholesterolemia, diabetes, and postmenopausal). Over the 5-year study period, the prevalence of CHD was 20.8% in the BACpositive group compared to 5.4% in the BAC-negative group (P<0.001). In the cohort without CHD at baseline, the BACpositive group was more likely to develop CHD (6.3% vs 2.3% respectively, P=0.003). The presence of BAC was a better 5-year predictor of incident CHD than hypertension, hypercholesterolemia, or fami ly history of CHD, independent of age and other confounders.
How Should I Change my Practice?
The presence of BAC on mammography is likely a marker for CHD and should be routinely reported. Clinicians evaluating patients with BACpositive mammograms should consider factoring it into their decision making regarding CHD prevention. What was Known? Hormone replacement therapy is the most effective treatment for relieving menopausal vasomotor symptoms, but its use is limited by increased rates of stroke and venous thromboembolic disease. 11 Non-hormonal therapies, including antidepressants and neuroleptics, reduce hot flashes by 40-84%. 12 Few studies have examined whether the effectiveness of non-hormonal therapies is influenced by race, menopausal status, or a personal history of anxiety or depression.
MANAGEMENT OF THE MENOPAUSAL WOMAN
What this Study Adds Women (n=250) with moderately severe hot flashes were randomized to escitalopram 10 mg daily or placebo for 8 weeks. Almost half of the study participants were African-American, and 14-23% reported mild depression or anxiety at baseline. After 8 weeks of treatment, patients in the escitalopram group experienced 1.40 fewer hot flashes per day and a reduction in severity than those in the placebo group. Although there was a substantial placebo effect, more women in the escitalopram group experienced at least a 50% reduction in hot flash frequency (55% vs 36%, p = 0.009). Race, menopausal status, and a history of depression or anxiety did not modify the treatment effect, and adverse events were few. Patient satisfaction and desire to continue with treatment was higher with escitalopram than placebo (70% vs 43%, p <0.001, and 64% vs 42%, p=0.005, respectively).
How Should I Change my Practice? Escitalopram may be a good treatment option for symptomatic women who want to avoid systemic hormone therapy, and will be effective even in those without anxiety or depression.
Renoux C, Dell'aniello S, Garbe E, Suissa S. Transdermal and oral hormone replacement therapy and the risk of stroke: a nested case-control study. BMJ. 2010;340:c2519.
What Was Known? Oral hormone therapy for relief of menopausal symptoms increases the risk for ischemic stroke. 13 Transdermal hormone therapy, while equally efficacious, avoids the hepatic first-pass effect and is less likely than oral therapy to increase cardiovascular risk markers.
14 To date, no studies have compared the effects of transdermal and oral hormone therapy on stroke risk.
What this Study Adds
Using a large British medical record database and a nested case-control study design, the investigators examined the rates of stroke among older women who were exposed to hormone therapy. How Should I Change my Practice? This study suggests that transdermal hormone therapy is safer than oral therapy. Although case control study designs have inherent biases, there is biological plausibility for these results based on prior studies. Providers should consider selecting transdermal routes of hormone administration to minimize the risks associated with systemic therapy. What was Known? In the Women's Health Initiative (WHI) placebo-controlled trial, women who were treated with combined estrogen and progestin (E/P) therapy had an increased risk of invasive breast cancer. Moreover, these breast cancers tended to be larger and at a more advanced stage at the time of detection. 15 Although the risk of breast cancer declined significantly after discontinuation of E/P 16 , the long-term effects of E/P on breast cancer incidence, characteristics at diagnosis, and breast cancer mortality are unclear.
What this Study Adds Although the WHI was stopped early in 2002, all subjects were followed for an additional 3 years, until the original trial completion date ("post-intervention phase"). Eighty-three percent of women consented to participate in the "extension phase," and data regarding breast cancer incidence and mortality were collected prospectively until 2009. In total, after a mean follow-up of 11.0 years, 678 cases of breast cancer were identified. Treatment with E/P, as compared to placebo, was associated with a significantly increased incidence of invasive breast cancer (HR 1.25, 95% CI 1.07-1.46). Women in the treatment group, as compared to those receiving placebo, were more likely to have positive lymph nodes at the time of diagnosis and were more likely to die from breast cancer (25 deaths vs 12 deaths, HR 1.96, 95% CI 1.00-4.04). Overall mortality after a diagnosis of breast cancer was higher in the E/P group than in the placebo group (51 deaths vs 31 deaths, HR 1.57, 95% CI 1.01-2.48).
How Should I Change my Practice? Treatment with E/P increases the incidence of invasive breast cancer, and the risk persists after discontinuation of therapy. Moreover, E/P increased breast cancer mortality and overall mortality, although the number of deaths in both groups was relatively small. In light of these new data, practitioners should continue to carefully weigh the risks and benefits of E/P therapy and counsel patients appropriately. [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] However, it has not previously been possible to estimate population prevalence or identify risk factors.
OSTEOPOROSIS AND BONE HEALTH
What this Study Adds Study investigators performed secondary analyses of three large randomized trials of bisphosphonates. These trials included the Fracture Intervention Trial (FIT), the FIT Long-Term Extension (FLEX) trial and the Health Outcomes and Reduced Incidence with Zolendronic Acid Once Yearly (HORIZON) Pivotal Fracture Trial (PFT). They had detailed records of fractures and radiographs to ascertain exact fracture locations and typical or atypical characteristics of the fracture. There were a total of 284 fractures among 14,195 women. Of the 284 fractures, 12 fractures in 10 patients were subtrochanteric or diaphyseal fractures, resulting in combined rate of 2.3 per 10,000 patient years. Compared with placebo, the relative hazard for alendronate in FIT was 1.03 (95% CI, 0.06, 16.46); the relative hazard for zolendronic acid use in HORIZON-PFT was 1.5 (0.25, 9.00), and the relative hazard for continued alendronate use in FLEX was 1.33 (0.12, 14.67). Fracture of the subtrochanteric or diaphyseal femur was very rare even in women on bisphosphonates for up to 10 years. Although all the point estimates showed an increased risk, the confidence intervals were wide because of the small number of events.
How Should I Change my Practice? Even if there is a small risk of atypical fracture associated with bisphosphonates, this must be weighed against the population benefits associated with the overall reduction in hip fractures among women with osteoporosis.
